Actelion’s Selexipag Meets Main Goal in Late-Stage Patient Study

June 16, 2014 6:36 AM

28 0

Actelion Ltd. (ATLN)’s experimental drug against a rare lung disease met the main goal of a late-stage study, potentially giving the drugmaker a pill to compete with inhalations and injections made by United Therapeutics Corp. (UTHR:US)

In a trial among 1,156 patients with pulmonary arterial hypertension, a deadly and incurable artery-narrowing disease, 39 percent fewer patients died or experienced a worsening of their ailment when treated with Actelion’s selexipag than those who got a placebo, the Allschwil, Switzerland-based comp...

Read more

To category page